HK Stock Market Move | 3SBIO (01530) is now up over 5%. Three indications of SSS68 injection have been approved for IND in China.

3SBIO (01530) is now up more than 5%, as of the time of publication, it has risen 5.13% to 23.36 Hong Kong dollars, with a turnover of 302 million Hong Kong dollars. On the news front, according to the latest announcement on the official website of the China National Medical Products Administration Center (CDE), the clinical trial application for the Class 1 new drug SSS68 injection (long-acting anti-APRIL/BAFF dual antibody) submitted by Shenyang 3SBIO Co., Ltd. has received implicit approval, with the intended indications for the treatment of primary membranous nephropathy (pMN), lupus nephritis (LN), and IgA nephropathy (IgAN). It is worth mentioning that SSS68 injection is the world's first dual antibody of APRILBAFF to enter the clinical stage. It is worth noting that on April 28th, the clinical trial application for the Class 1 therapeutic bioproduct SSGJ-706 injection, independently developed by 3SBIO, officially received acceptance. SSGJ-706 is a new generation of tumor immunotherapy drug developed completely independently by 3SBIO. It is classified as a Class 1 new drug for therapeutic bioproducts and is one of the few PD-1/IL-15 dual functional fusion proteins that have entered the IND application phase in China. The core innovation lies in solving the clinical application pain points of immune cell cytokine drugs.